Vancouver based Maynards was established in 1902, focused initially on the auction of furnishings and fine arts. The firm has since grown to provide liquidation and valuation services to a broad range of industry sectors with global reach from offices located in the United States, Canada, Germany, UK, China and Japan. In a sealed bid sale closing on the 31st of December, Maynards will sell the contents of the 100-acre facility in South Gloucestershire, UK formerly operated by Avara.
Avara is a global contract manufacturing organisation specialising in the manufacture of sterile fill-finish injectable products, oral solid dose drug products and integrated packaging. The 100-acre Avlon Works site in South Gloucestershire was previously operated by AstraZenceca who sold it to Avara in 2016. Maynards real estate partner EDC acquired the plant in December 2020.
The site features: two large-scale milling facilities with Hosakawa mills and Matcon bin charging; five large-scale cGMP API plants for the large volume commercial manufacture of APIs and intermediates, with 6-10 m3 reactor capacity, pressure filter, conical and centrifuge drying; cGMP large scale laboratory with 10-100L reactor capacity; site support equipment; warehouse equipment; spares inventory valued at £25M+; workshops; offices; building structures and much, much more.